Study finds origin of ovarian cancer, characterises genetic mutation putting women at high risk

During a recent study, a team of researchers found the origin of common ovarian cancer, allowing them to characterise how a genetic mutation puts women at high risk for this cancer.

The research has been published in the ‘Cell Reports Journal’. Ovarian cancer is the leading cause of gynaecologic cancer deaths in the US, in part because symptoms are often subtle and most tumours elude detection until they are in advanced stages and have spread past the ovaries.

While the lifetime risk of developing ovarian cancer is less than 2 per cent for the general female population, the estimated risk for women who carry a mutation in the so-called BRCA-1 gene is between 35 per cent and 70 per cent, according to the American Cancer Society.

Faced with such steep odds, some women with BRCA-1 mutations choose to have their breasts or ovaries and fallopian tubes surgically removed even though they may never develop cancers in these tissues.

The new study findings could help physicians pinpoint which of these women are most likely to develop ovarian cancer in the future–and which are not–and pursue new ways to block the process or treat cancer.”

“We created these fallopian organoids using cells from women with BRCA-1 mutations who had ovarian cancer,” explained Clive Svendsen, PhD, executive director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute.

“Our data support recent research indicating that ovarian cancer in these patients actually begins with cancerous lesions in the fallopian tube linings. If we can detect these abnormalities at the outset, we may be able to short-circuit ovarian cancer,” Svendsen added.

Svendsen, professor of Biomedical Sciences and Medicine, is the co-corresponding author of the new study, conducted at Cedars-Sinai. The other co-corresponding author is Beth Karlan, MD, now professor of Obstetrics and Gynaecology in the David Geffen School of Medicine at UCLA and director of cancer population genetics at the UCLA Jonsson Comprehensive Cancer Centre.

To make their discoveries, the research team generated induced pluripotent stem cells (IPSCs), which can produce any type of cell.

They started with blood samples taken from two groups of women: young ovarian cancer patients who had the BRCA-1 mutation and a control group of healthy women.

Investigators then used the iPSCs to produce organoids modelling the lining of fallopian tubes and compared the organoids in the two groups.

“We were surprised to find multiple cellular pathologies consistent with cancer development only in the organoids from the BRCA-1 patients,” said Nur Yucer, PhD, a project scientist in Svendsen’s lab and the first author.

“Organoids derived from women with the most aggressive ovarian cancer displayed the most severe organoid pathology,” Yucer added.

Besides showing how ovarian cancer is “seeded” in the fallopian tubes of women with mutated BRCA-1, the organoid technology potentially can be used to determine if a drug might work against the disease in an individual, Svendsen said.

Each organoid carried the genes of the person who provided the blood sample, making it a “twin” of that person’s own fallopian tube linings. Multiple drugs can be tested on the organoids without exposing the patient to them.”

This study represents an exciting use of IPSCs, bringing us closer than ever to significantly improving the outcomes for women with this common type of ovarian cancer,” said Jeffrey Golden, MD, vice dean of Research and Graduate Education and director of the Burns and Allen Research Institute at Cedars-Sinai.

“Building on these findings may one day allow us to provide early, lifesaving detection of ovarian cancer in women who carry the BRCA-1 mutation and create effective, individualized prevention and, if necessary, treatment strategies,” Golden added.